MetaSight Diagnostics Raises $8M in Over-Subscribed Series A Funding Round
Summary
"Originating at the Technion Israel Institute of Technology and founded in 2021, MetaSight is positioned at the forefront of discovery and development of early-stage screening and diagnosis of diseases such as colorectal cancer (CRC) and Metabolic dysfunction-associated steatohepatitis (MASH). Leveraging the worlds largest dataset of analyzed serum samples linked to continuously updated individual longitudinal electronic medical records, MetaSight has developed a high throughput, sensitive and affordable, mass spectrometry-based diagnostics discovery engine with shorter turnaround times and lower costs than other methods available today. "Our confidence in MetaSights innovative approach to diagnostics development and its potential to reshape the future of healthcare drives our investment," said Dr. Tomer Berkovitz, Managing Partner at aMoon, and new addition to the companys board of directors. "This commitment reflects our longstanding support of Israels vibrant HealthTech sector, to which aMoon funds have proudly invested over $300 million to date in 19 Israeli companies. "The company is currently in discussions with multiple strategic players regarding its lead programs MASH and CRC and is planning to make its tests available in selected markets in 2025.MetaSight is headquartered in Rehovot, Israel, and will use the Series A funding to further develop its pipeline and engage in additional strategic partnerships.MetaSight Diagnostics, a health technology company, is on a mission to create affordable and precise liquid biopsy diagnostics for early detection of a variety of chronic and acute diseases, utilizing proprietary, cost-effective mass spectrometry technologies (metabolomics, lipidomics and proteomics).